Publications by authors named "Ines Mariana Lourenco"
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-Like peptide-1 receptor agonists (GLP-1 RA) are recommended in people with type 2 diabetes (T2D) for glycaemic control and for people with high cardiovascular risk. However, current guidelines do not specifically address the role of initial early combination therapy with SGLT2i and GLP-1 RA or dual gastric inhibitory polypeptide (GIP)/GLP-1 RA, but rather sequential initiation with either in T2D. This review synthesizes the available evidence on the use of SGLT2i and GLP-1-based therapies for T2D and provides a rationale for their combination.
View Article and Find Full Text PDFAim: Metabolic syndrome (MetS) is associated with higher cardiovascular and metabolic risks, as well as with psychosocial disorders. Data regarding quality of life (QoL) in patients with MetS, point towards a significative association between MetS and a worse QoL. It remains unclear whether MetS components and non-alcoholic fatty liver disease (NAFLD) are associated with QoL in these individuals.
View Article and Find Full Text PDFArticle Synopsis
- Low levels of triiodothyronine (T3) are prevalent in heart failure (HF) patients, and this study aimed to assess the effects of low and replacement doses of T3 in a rat model of HF with preserved ejection fraction (HFpEF).
- Four groups were evaluated: lean control rats, obese rats with HFpEF, and two groups of obese rats treated with either low or replacement doses of T3, administered via drinking water over 11 weeks.
- Results indicated that T3 treatment improved metabolic profiles and cardiac function, with the high T3 dose restoring myocardial T3 levels and yielding benefits in calcium handling and heart function, despite no change in overall exercise capacity (VOmax).